VLON RSI Chart
Last 7 days
5%
Last 30 days
-17.6%
Last 90 days
-58.8%
Trailing 12 Months
-93.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2020 | 0 | 0 | 0 | 100.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 13, 2022 | thorell marella | sold | - | - | -28,517 | - |
Jul 01, 2022 | thorell marella | acquired | - | - | 38,023 | - |
Jun 04, 2021 | kelly leanne m. | bought | 6,152 | 4.08 | 1,508 | chief financial officer |
Jun 03, 2021 | kelly leanne m. | bought | 4,394 | 4.05 | 1,085 | chief financial officer |
Jun 02, 2021 | kelly leanne m. | bought | 14,628 | 4.00 | 3,657 | chief financial officer |
May 26, 2021 | payne joseph e | bought | 30,600 | 4.5 | 6,800 | - |
May 25, 2021 | payne joseph e | bought | 41,195 | 3.85 | 10,700 | - |
Feb 12, 2021 | ammer richard | acquired | 301,203 | 6.4 | 47,063 | - |
Feb 12, 2021 | salmon pharma gmbh | acquired | 301,203 | 6.4 | 47,063 | - |
Feb 12, 2021 | baker david charles | bought | 8,000 | 8.00 | 1,000 | chief executive officer |
Unveiling Vallon Pharmaceuticals, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Vallon Pharmaceuticals, Inc. News
Income Statement (Quarterly) | |||||
Description | (%) Q/Q | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Revenue | - | - | - | - | 100 |
Operating Expenses | 41.4% | 1,461 | 1,033 | 1,135 | 1,258 |
S&GA Expenses | -40.2% | 180 | 300 | 327 | 375 |
R&D Expenses | 74.8% | 1,282 | 733 | 808 | 883 |
Interest Expenses | 654.2% | 67.00 | -12.00 | -12.00 | -2.00 |
Net Income | -40.6% | -1,469 | -1,045 | -1,147 | -1,161 |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | 55.2% | 4,587 | 2,956 | 4,404 | 5,642 | 2,097 | 3,833 | 5,569 | 8,007 | 5,944 | 8,335 | 10,140 | 11,647 | 14,600 | 955 |
Current Assets | 50.9% | 4,428 | 2,934 | 4,367 | 5,592 | - | 312 | 5,569 | 7,838 | 5,757 | 96.00 | 9,916 | 11,404 | 14,338 | 674 |
Cash Equivalents | 126.3% | 4,091 | 1,808 | 3,488 | 4,799 | 1,665 | 9.00 | 104 | 9.00 | 2,543 | 90.00 | 5,884 | 10,460 | 12,980 | 109 |
Net PPE | -12.5% | 7.00 | 8.00 | 9.00 | 9.00 | - | 4.00 | - | - | - | 3.00 | - | - | 1.00 | 2.00 |
Liabilities | -33.7% | 1,789 | 2,697 | 2,177 | 1,604 | 2,066 | 2,008 | 2,110 | 4,341 | 2,584 | 2,517 | 1,411 | 1,794 | 2,573 | 2,409 |
Current Liabilities | -37.7% | 1,680 | 2,697 | 2,177 | 1,604 | - | 1,994 | 2,110 | 4,322 | 2,538 | 2,445 | 1,313 | 1,671 | 2,427 | 2,225 |
Shareholder's Equity | 980.3% | 2,798 | 259 | 2,227 | 4,038 | 31.00 | 2,342 | 3,459 | 3,666 | 3,360 | 5,818 | 8,729 | 9,853 | 12,027 | - |
Retained Earnings | -6.0% | -33,420 | -31,533 | -29,529 | -27,392 | -31,322 | -18,496 | -27,343 | -26,310 | -24,537 | -21,902 | -18,806 | -17,549 | -15,237 | -12,599 |
Additional Paid-In Capital | 13.9% | 36,218 | 31,792 | 31,756 | 31,430 | 31,353 | 16,871 | 30,802 | 29,978 | 27,903 | 27,722 | 27,536 | 27,402 | 27,264 | 11,145 |
Shares Outstanding | 395.0% | 3,196 | 646 | 422 | 2,956 | 449 | - | 12,733 | 851 | 6,813 | 6,813 | 6,450 | 6,265 | - | - |
Float | - | - | - | - | 9,500 | - | - | - | 5,200 | - | - | - | 22,900 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | 60.4% | -2,203 | -5,560 | -1,311 | -3.00 | -2,116 | -844 | -125 | 2,174 | -2,290 | -1,583 | -1,289 | -2,492 | -2,948 | -808 | -1,064 | -1,068 | -766 |
Share Based Compensation | 2.8% | 37.00 | 36.00 | 326 | -59.00 | 85.00 | 25.00 | - | -181 | 181 | 186 | 134 | 138 | 168 | 39.00 | 52.00 | 28.00 | 35.00 |
Cashflow From Investing | - | - | - | - | -8.00 | - | -3.00 | - | -1,154 | 1,154 | -576 | -3,266 | - | - | - | - | - | -2.00 |
Cashflow From Financing | 15.6% | 4,486 | 3,880 | - | 6,917 | - | 752 | 220 | 58.00 | -23.00 | -23.00 | -21.00 | -28.00 | 15,819 | -7.00 | -11.00 | 43.00 | -29.00 |
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 933 | $ 116 |
General and administrative | 962 | 872 |
Total operating expenses | 1,895 | 988 |
Loss from operations | (1,895) | (988) |
Change in fair value of warrant liability | 2 | 0 |
Interest income (expense), net | 6 | (1,162) |
Net loss | $ (1,887) | $ (2,150) |
Net loss per share of common stock, basic (in usd per share) | $ (0.46) | $ (15.04) |
Net loss per share of common stock, diluted (in usd per share) | $ (0.46) | $ (15.04) |
Weighted-average common shares outstanding, basic (in shares) | 4,127,448 | 142,988 |
Weighted-average common shares outstanding, diluted (in shares) | 4,127,448 | 142,988 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 4,091 | $ 1,808 |
Prepaid expenses and other current assets | 337 | 1,126 |
Total current assets | 4,428 | 2,934 |
Property and equipment, net | 7 | 8 |
Operating lease right-of-use assets | 152 | 14 |
Total assets | 4,587 | 2,956 |
Current liabilities: | ||
Accounts payable | 637 | 1,410 |
Accrued expenses | 999 | 1,270 |
Warrant liability | 1 | 3 |
Operating lease liabilities, current | 43 | 14 |
Total current liabilities | 1,680 | 2,697 |
Operating lease liabilities, non-current | 109 | 0 |
Total liabilities | 1,789 | 2,697 |
Commitments and contingencies (Note 11) | ||
Stockholders' equity: | ||
Common stock, $0.0001 par value; 250,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 3,196,488 and 645,738 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 0 | 0 |
Additional paid-in-capital | 36,218 | 31,792 |
Accumulated deficit | (33,420) | (31,533) |
Total stockholders’ equity | 2,798 | 259 |
Total liabilities and stockholders' equity | $ 4,587 | $ 2,956 |